{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:21:37Z","timestamp":1777310497779,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T00:00:00Z","timestamp":1329782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clofarabine is a second\u2010generation purine nucleoside analog and has significant anti\u2010leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA\u2010damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians. Pediatr Blood Cancer 2012;59:417\u2013422. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/pbc.24112","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T19:47:54Z","timestamp":1329853674000},"page":"417-422","source":"Crossref","is-referenced-by-count":22,"title":["Clofarabine in pediatric acute leukemia: Current findings and issues"],"prefix":"10.1002","volume":"59","author":[{"given":"Nobuko","family":"Hijiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elly","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Arceci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.0421"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21005"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-081364"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3294"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.09.70"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8554"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-374710"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.185"},{"key":"e_1_2_8_10_2","doi-asserted-by":"crossref","unstructured":"CooperT AlonzoTA GerbingRB et al.A report from the children's oncology group on the safety of clofarabine in combination with cytarabine in pediatric patients with relapsed acute leukemia.The American Society of Hematology 53rd annual meeting 2010 (3076).","DOI":"10.1182\/blood.V114.22.3076.3076"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07882.x"},{"key":"e_1_2_8_12_2","first-page":"2386","article-title":"Effects of 2\u2010chloro\u20109\u2010(2\u2010deoxy\u20102\u2010fluoro\u2010beta\u2010D\u2010arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5\u2032\u2010triphosphate","volume":"51","author":"Parker WB","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_8_13_2","first-page":"2438","article-title":"Biochemical pharmacology and resistance to 2\u2010chloro\u20102'\u2010arabino\u2010fluoro\u20102'\u2010deoxyadenosine, a novel analogue of cladribine in human leukemic cells","volume":"5","author":"Lotfi K","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3537"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/15257770008033020"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00080a029"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050889"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.7.2970"},{"key":"e_1_2_8_19_2","volume-title":"Response of subcutaneous HT\u201029 colon tumor to combination treatment with oxaliplatin and clofarabine","author":"Dykes D","year":"2003"},{"key":"e_1_2_8_20_2","volume-title":"Response of subcutaneous CCRF\u2010CEM leukemia to combination treatment with Ara C and clofarabine","author":"Dykes D","year":"2002"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.031"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0925"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4242"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2122"},{"key":"e_1_2_8_25_2","doi-asserted-by":"crossref","first-page":"abstract #1859","DOI":"10.1182\/blood.V108.11.1859.1859","article-title":"BIOV\u2010111a European phase II trial of clofarabine (Evoltra) in refractroy and relapsed childhood acute lymphoblastic leukemia","volume":"108","author":"Kearns PMG","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1933"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23816"},{"key":"e_1_2_8_28_2","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4\u2010hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi T","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1414"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2055"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3509"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-284968"},{"key":"e_1_2_8_33_2","doi-asserted-by":"crossref","unstructured":"ZhangY ZhangJ ShahriarM et al.Clofarabine induces hypomethylation of DNA and expression of cancer\u2010testis antigens.ASH Annual Meeting Abstracts2008; 112: 379.","DOI":"10.1182\/blood.V112.11.379.379"},{"key":"e_1_2_8_34_2","first-page":"4601","article-title":"Influence of clofarabine on transcriptional activity of PTEN, APC, RARB2, ZAP70 genes in K562 cells","volume":"30","author":"Majda K","year":"2010","journal-title":"Anticancer Res"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08752.x"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24112","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T03:20:40Z","timestamp":1696908040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,21]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/pbc.24112"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24112","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,21]]}}}